Small Bowel Cancer in Crohn's Disease.
Ilaria FaggianiFerdinando D'AmicoFederica FurfaroAlessandra ZilliTommaso Lorenzo ParigiClelia CiceroneGionata FiorinoLaurent Peyrin-BirouletSilvio DaneseMariangela AlloccaPublished in: Cancers (2024)
Crohn's disease (CD) is a chronic inflammatory bowel disease (IBD) that frequently affects the small bowel. Individuals diagnosed with CD are at increased risk of developing bowel cancer compared to the general population. Small bowel cancer is a rare but significant CD complication. Adenocarcinoma represents the most prevalent of these neoplasms, followed by neuroendocrine tumors and sarcomas. The primary risk factors identified are being of the male sex, disease duration, previous surgical intervention, perianal disease, and chronic inflammation. The precise etiology remains unclear. Another crucial issue concerns the role of immunomodulators and advanced therapies. By inhibiting inflammation, these therapies can reduce the risk of cancer, which is often initiated by the inflammation-dysplasia-adenocarcinoma sequence. In accordance with the most recent guidelines, it is not necessary to conduct surveillance in patients with small bowel cancer among CD patients, as it is considered a rare disease. Nevertheless, it is of significant importance for gastroenterologists to be aware of this potential CD complication, as well as the patients who are most at risk of developing it. The purpose of this review is to provide a comprehensive overview of CD-SBC, focusing on epidemiology, etiopathogenesis, risk factors, diagnosis, and the role of advanced therapies in CD-SBC.
Keyphrases
- small bowel
- papillary thyroid
- risk factors
- squamous cell
- end stage renal disease
- oxidative stress
- ejection fraction
- squamous cell carcinoma
- nk cells
- newly diagnosed
- chronic kidney disease
- public health
- randomized controlled trial
- lymph node metastasis
- prognostic factors
- neuroendocrine tumors
- radiation therapy
- peritoneal dialysis
- risk assessment
- young adults